NCT01661244View on ClinicalTrials.gov

A Study to Investigate the Safety and Tolerability of a New Inhaled Formulation of RV568 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

February 28, 2013

Study Completion Date

February 28, 2013

Conditions
COPDHealthy Volunteers
Interventions
DRUG

RV568 single dose

Safety and tolerability of single escalating doses in normal human volunteers

DRUG

RV568 matching placebo single dose

Safety and tolerability of escalating repeat doses in normal human volunteers.

DRUG

RV568 repeat dose

Safety and tolerability of escalating repeat doses in normal human volunteers.

DRUG

RV568 matching placebo repeat dose

Safety and tolerability of escalating repeat doses in normal human volunteers.

Trial Locations (1)

NW10 7EW

London

All Listed Sponsors
lead

Respivert Ltd

INDUSTRY

NCT01661244 - A Study to Investigate the Safety and Tolerability of a New Inhaled Formulation of RV568 in Healthy Volunteers | Biotech Hunter | Biotech Hunter